Immune Checkpoint Molecules Have Prognostic Value in Ovarian Cancer, Study Reports

Immune Checkpoint Molecules Have Prognostic Value in Ovarian Cancer, Study Reports
The immune checkpoint molecules PD-L1 and TIM-3 have prognostic value in people with ovarian cancer who have not yet received chemotherapy. But while low levels of TIM-3 were linked to longer survival rates, a study unexpectedly showed that high levels of PD-L1 predicted better patient survival. The findings also point to TIM-3 inhibitors as a potentially promising approach for those with ovarian cancer who have not yet received chemotherapy. The study, "TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer," was published in the journal Clinical Cancer Research. It has become abundantly clear in recent years that the immune system plays a critical role in the development of cancer, scientists say. This has led to the idea that the immune status of an individual tumor — specifically, what kinds of immune cells are present, how many there are, and what markers they are expressing — can help to develop prognoses for patients. Researchers now set out to clarify the roles of a number of immune cells and markers in high-grade serous carcinoma, the most common type of ovarian cancer. They examined 80 tumor biopsies from ovarian cancer patients who had undergone surgery
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *